Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Long, Noncoding RNA Linked to Lung Cancer Metastasis

By LabMedica International staff writers
Posted on 20 Feb 2013
A recent paper described the functional significance of the long, noncoding RNA (lncRNA) MALAT1 in the process of lung cancer metastasis.

The vast majority of RNA molecules are transcribed by DNA segments that do not code for proteins. More...
These RNAs, which arbitrarily have been defined as containing more than 200 nucleotides, are called long, noncoding RNAs and are clearly differentiated from small, inhibitory RNAs such as short, inhibitory RNA (siRNA) and microRNA (miRNA).

MALAT1 (metastasis associated lung adenocarcinoma transcript 1) also known as NEAT2 (noncoding nuclear-enriched abundant transcript 2) is a large, infrequently spliced noncoding RNA. This molecular species is expressed in the nucleus and is highly conserved among mammals. It is associated with metastasis, and positively regulates cell motility via the transcriptional and/or post-transcriptional regulation of motility-related genes.

To study the role of MALAT1 in metastasis investigators at the German Cancer Research Center (Heidelberg) developed a MALAT1 knockout model in human lung tumor cells by genomically integrating RNA destabilizing elements using zinc finger nucleases that destroyed molecules of MALAT1 as soon as they were manufactured. In this manner, the investigators were able to silence MALAT1 expression by reducing the level of this molecular species in lung cancer cells by more than 1,000-fold.

The investigators reported in the December 14, 2012, online edition of the journal Cancer Research that the MALAT1-deficient cells were impaired in migration and formed fewer tumor nodules in a mouse xenograft.

Mice that had been injected with human lung cancer cells were treated with antisense oligonucleotides directed at MALAT1. This treatment prevented metastasis formation after tumor implantation. The animals' lungs showed fewer and smaller tumor nodules than those of control animals that had not been given the antisense nucleotides.

"The more MALAT1 tumor cells produce, the higher the odds for metastasis and a very unfavorable course of the disease," said senior author Dr. Sven Diederichs, a group leader in molecular RNA biology and cancer at the German Cancer Research Center. "Ten years after we discovered MALAT1 as a predictive marker in lung cancer, we now understand how this noncoding RNA influences metastasis. Moreover, this RNA has turned out to be a potential target for an innovative treatment with antisense RNAs."

Related Links:
German Cancer Research Center



Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
8-Channel Pipette
SAPPHIRE 20–300 µL
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.